REG-Pharming Group reports third quarter 2026 financial results; strong revenue growth, Joenja APDS expansion and CVID topline data in November
Pharming reported Q3 2026 revenue of $117.6 million, up 21% year-over-year and ahead of market expectations, with operating profit up 89% to $29.9 million. Joenja (leniolisib) grew 58% to $23.8 million on U.S. pediatric label approval and launches in Germany and Japan, while RUCONEST returned to growth at +14% to $93.8 million. Cash rose to $190.9 million.
Key figures
- Eps
- 0.032
- Revenue
- 117600000
- Guidance
- 2026 total revenues US$380 million - US$390 million, tightened from prior US$375 million - US$395 million
- Revenue Yoy
- 21%
- Net profit
- 22400000
- Gross profit
- 102200000
- Cash position
- 190900000
- Joenja revenue
- 23800000
- Operating profit
- 29900000
- Ruconest revenue
- 93800000
- Joenja revenue yoy
- 58%
- Operating profit yoy
- 89%
- Ruconest revenue yoy
- 14%
- Operating cash flow q3
- 32400000
- Operating cash flow ytd
- 24700000
- Spleen volume reduction
- 26.4%
- Us joenja paid patients
- 136
- Adjusted operating profit q3
- 35000000
AI analysis
Red flags4 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.